SCHEMBL4987332

SCHEMBL4987332

CNc1ccc(C=Cc2cc(=O)c3cc(O)ccc3o2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 9/20 0.67
MAOB P27338 5/20 0.51
MAPT P10636 4/20 0.51
KDM4E B2RXH2 3/20 0.51
MAOA P21397 2/20 0.51
HPGD P15428 3/20 0.49
ALDH1A1 P00352 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
STS P08842 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10144901 1.00 APP (0.67) APPMAOBMAPTKDM4EMAOA
SCHEMBL4987018 0.85 APP (0.51) APPMAOBMAPTKDM4EMAOA
SCHEMBL10144979 0.85 APP (0.62) APPMAOBMAPTKDM4EMAOA
SCHEMBL4989048 0.85 APP (0.62) APPMAOBMAPTKDM4EMAOA
SCHEMBL10144976 0.85 APP (0.51) APPMAOBMAPTKDM4EMAOA
SCHEMBL10144896 0.83 APP (0.65) APPMAOBMAPTKDM4EMAOA
SCHEMBL4987282 0.83 APP (0.65) APPMAOBMAPTKDM4EMAOA
SCHEMBL10144898 0.83 MAOA (0.74) APPMAOBMAPTKDM4EMAOA
SCHEMBL4983225 0.83 MAOA (0.74) APPMAOBMAPTKDM4EMAOA
SCHEMBL7575770 0.83 MAPT (0.71) APPMAOBMAPTKDM4EMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 APP 1/4885MAOB 2191/4885MAPT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.